Tumor Necrosis Factor Alpha Antagonists and Occurrence of Autoantibodies in Inflammatory Bowel Disease Patients: A Single Center Experience

Risultato della ricerca: Article

Abstract

Background & Aims: Appearance of auto antibodies have been describedduring anti-tumor necrosis factor (TNF) alpha therapy; however, their prevalence andclinical relevance are still unclear. We investigated prevalence of autoantibodiesininflammatory bowel diseases (IBD) patients on anti-TNFα treatment and occurrence ofclinical symptoms.Methods: Titers of ANA, anti-dsDNA, SMA, AMA, LKM were evaluated from bloodsamples in patients receiving anti-TNFα inhibitor (adalimumab,infliximab).Results: Among 39 patients treated with anti-TNFα therapy, twenty of themdeveloped ANA, mostly induced by infliximab. 55% ANA positive patients developedperipheral polyarthralgias with no need for intervention. No patients with positiveautoantibodies developed a drug-induced lupus. The incidence of dsDNA, SMA andAMA was low and was not associated with autoimmune disease.Conclusions: Immune response induced by anti-TNFα is restricted to ANA, withlower prevalence of dsDNA antibodies, SMA and AMA. Further studies are needed toclarify the role of autoantibodies during anti-TNFα therapy.
Lingua originaleEnglish
pagine (da-a)1046-1050
Numero di pagine5
RivistaJSM GASTROENTEROLOGY AND HEPATOLOGY
Volume3
Stato di pubblicazionePublished - 2015

Fingerprint

Inflammatory Bowel Diseases
Autoantibodies
Tumor Necrosis Factor-alpha
Antibodies
Arthralgia
Therapeutics
Autoimmune Diseases
Incidence
Pharmaceutical Preparations

Cita questo

@article{38d1602167de4668acc6b1ba10962da4,
title = "Tumor Necrosis Factor Alpha Antagonists and Occurrence of Autoantibodies in Inflammatory Bowel Disease Patients: A Single Center Experience",
abstract = "Background & Aims: Appearance of auto antibodies have been describedduring anti-tumor necrosis factor (TNF) alpha therapy; however, their prevalence andclinical relevance are still unclear. We investigated prevalence of autoantibodiesininflammatory bowel diseases (IBD) patients on anti-TNFα treatment and occurrence ofclinical symptoms.Methods: Titers of ANA, anti-dsDNA, SMA, AMA, LKM were evaluated from bloodsamples in patients receiving anti-TNFα inhibitor (adalimumab,infliximab).Results: Among 39 patients treated with anti-TNFα therapy, twenty of themdeveloped ANA, mostly induced by infliximab. 55{\%} ANA positive patients developedperipheral polyarthralgias with no need for intervention. No patients with positiveautoantibodies developed a drug-induced lupus. The incidence of dsDNA, SMA andAMA was low and was not associated with autoimmune disease.Conclusions: Immune response induced by anti-TNFα is restricted to ANA, withlower prevalence of dsDNA antibodies, SMA and AMA. Further studies are needed toclarify the role of autoantibodies during anti-TNFα therapy.",
author = "Almasio, {Pier Luigi} and Antonio Craxi and Anna Licata",
year = "2015",
language = "English",
volume = "3",
pages = "1046--1050",
journal = "JSM GASTROENTEROLOGY AND HEPATOLOGY",
issn = "2373-9487",

}

TY - JOUR

T1 - Tumor Necrosis Factor Alpha Antagonists and Occurrence of Autoantibodies in Inflammatory Bowel Disease Patients: A Single Center Experience

AU - Almasio, Pier Luigi

AU - Craxi, Antonio

AU - Licata, Anna

PY - 2015

Y1 - 2015

N2 - Background & Aims: Appearance of auto antibodies have been describedduring anti-tumor necrosis factor (TNF) alpha therapy; however, their prevalence andclinical relevance are still unclear. We investigated prevalence of autoantibodiesininflammatory bowel diseases (IBD) patients on anti-TNFα treatment and occurrence ofclinical symptoms.Methods: Titers of ANA, anti-dsDNA, SMA, AMA, LKM were evaluated from bloodsamples in patients receiving anti-TNFα inhibitor (adalimumab,infliximab).Results: Among 39 patients treated with anti-TNFα therapy, twenty of themdeveloped ANA, mostly induced by infliximab. 55% ANA positive patients developedperipheral polyarthralgias with no need for intervention. No patients with positiveautoantibodies developed a drug-induced lupus. The incidence of dsDNA, SMA andAMA was low and was not associated with autoimmune disease.Conclusions: Immune response induced by anti-TNFα is restricted to ANA, withlower prevalence of dsDNA antibodies, SMA and AMA. Further studies are needed toclarify the role of autoantibodies during anti-TNFα therapy.

AB - Background & Aims: Appearance of auto antibodies have been describedduring anti-tumor necrosis factor (TNF) alpha therapy; however, their prevalence andclinical relevance are still unclear. We investigated prevalence of autoantibodiesininflammatory bowel diseases (IBD) patients on anti-TNFα treatment and occurrence ofclinical symptoms.Methods: Titers of ANA, anti-dsDNA, SMA, AMA, LKM were evaluated from bloodsamples in patients receiving anti-TNFα inhibitor (adalimumab,infliximab).Results: Among 39 patients treated with anti-TNFα therapy, twenty of themdeveloped ANA, mostly induced by infliximab. 55% ANA positive patients developedperipheral polyarthralgias with no need for intervention. No patients with positiveautoantibodies developed a drug-induced lupus. The incidence of dsDNA, SMA andAMA was low and was not associated with autoimmune disease.Conclusions: Immune response induced by anti-TNFα is restricted to ANA, withlower prevalence of dsDNA antibodies, SMA and AMA. Further studies are needed toclarify the role of autoantibodies during anti-TNFα therapy.

UR - http://hdl.handle.net/10447/199832

M3 - Article

VL - 3

SP - 1046

EP - 1050

JO - JSM GASTROENTEROLOGY AND HEPATOLOGY

JF - JSM GASTROENTEROLOGY AND HEPATOLOGY

SN - 2373-9487

ER -